No Data
No Data
Income Investing: 6 Large-Cap Stocks With Growing Dividends
Dow Drops 138 Points On Losses For Shares Of American Express, Merck
Express News | Amgen Says FDA Shifted the Pdufa Date by 3 Months to Jan 17, 2025 to Allow Additional Time for Review of Supplemental Data Recently Submitted to Agency
Express News | Amgen Says FDA Has Extended Review Period for Lumakras in Combination With Vectibix for Treating Some Colorectal Cancer Patients
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
Bernstein: First coverage of eli lilly and co, gilead sciences, and amgen all rated as "outperforming the large cap".
Bernstein initiated coverage on eli lilly and co, gilead sciences, and amgen, all with an 'outperform' rating. Bernstein stated that the bullish rating on gilead and amgen is based on optimistic expectations for key assets to achieve revenue growth from now until 2030, including gilead's HIV PreEP treatment lenacapavir, amgen's weight loss drug MariTide, and rare disease investment portfolio. As for eli lilly and co, Bernstein stated that the rating "depends on how it leverages the cash obtained from weight loss drugs", eli lilly and co is ready to use a diversified investment portfolio and leverage weight loss drugs for growth. In addition, Bern
amiable Llama_6295 : hippee hippee